Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.

Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.

BACKGROUND: Platinum-based standard chemotherapy improves survival of ovarian cancer (OC), but the five-year survival rate remains below 50%. Antiangiogenic agents (7.5 or 15 mg/kg Bevacizumab, Bev) plus to standard chemotherapy improve progression-free survival (PFS) not overall survival (OS) in co...

Full description

Bibliographic Details
Main Authors: Mingyi Zhou, Ping Yu, Xiujuan Qu, Yunpeng Liu, Jingdong Zhang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3853655?pdf=render

Similar Items

Similar Items